Ad26.RSV.preF

BIOLOGICAL4 trials

Sponsors

Janssen Vaccines & Prevention B.V.

Conditions

HealthyRespiratory Syncytial Virus

Phase 1

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion (Ad26.RSV.Pre-F) Vaccine in RSV-Seronegative Toddlers 12 to 24 Months of Age

CompletedNCT03606512

Janssen Vaccines & Prevention B.V.Respiratory Syncytial Virus

Start: 2019-01-21End: 2021-11-02Updated: 2025-02-04

A Shedding Study of Adenovirus Serotype 26 Based Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF) Vaccine in Adults

CompletedNCT03795441

Janssen Vaccines & Prevention B.V.Healthy

Start: 2019-01-07End: 2019-07-28Updated: 2019-08-30

Phase 2

An Exploratory Study to Evaluate the Prophylactic Efficacy of a Single Immunization of Ad26.RSV.preF Against Respiratory Syncytial Virus Infection in a Virus Challenge Model in Healthy 18 to 50 Year-old Adults

CompletedNCT03334695

Janssen Vaccines & Prevention B.V.Healthy

Start: 2017-10-16End: 2018-11-27Updated: 2025-02-04

A Study to Evaluate the Safety and Immunogenicity of Seasonal Influenza Vaccine and an Adenovirus Serotype 26- Based Vaccine Encoding for the Respiratory Syncytial Virus Pre-fusion F Protein (Ad26.RSV.preF), With and Without Co-administration, in Adults Aged 60 Years and Older in Stable Health

CompletedNCT03339713

Janssen Vaccines & Prevention B.V.Healthy

Start: 2017-12-07End: 2018-07-23Updated: 2025-02-04

Related Papers

A Phase 1/2a Study Evaluating Safety and Immunogenicity of Ad26.RSV.preF in RSV-seronegative Toddlers Aged 12–24 Months

Open Forum Infectious Diseases2024-08-086 citations

Prevention of Respiratory Syncytial Virus Infection in Healthy Adults by a Single Immunization of Ad26.RSV.preF in a Human Challenge Study.

2022-08-0165 citations

Safety and Immunogenicity of the Ad26.RSV.preF Investigational Vaccine Coadministered With an Influenza Vaccine in Older Adults

The Journal of Infectious Diseases2020-08-2656 citations

902. A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy of a Single Immunization of Ad26.RSV.preF against RSV Infection in a Viral Challenge Model in Healthy Adults

Open Forum Infectious Diseases2019-10-0110 citations

2775. Safety and Immunogenicity of a Seasonal Influenza Vaccine and Ad26.RSV.preF Vaccine With and Without Co-Administration: A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study in Adults Aged ≥ 60 Years

Open Forum Infectious Diseases2019-10-01